Sojeong Yi

Sojeong Yi

Auto-generated profile, based on publicly available information

Sojeong Yi

Alnylam Pharmaceuticals, Inc Cambridge Massachusetts USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 May 2017 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
SYS. Yi
S. Yi
HLH. Lee
H. Lee
SJS. B. Jang
S. B. Jang
HBH. M. Byun
H. M. Byun
SYS. H. Yoon
S. H. Yoon
KYK.‐S. Yu
K.‐S. Yu

1 January 2019 in Translational and Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
SYSumin Yoon
Sumin Yoon
SYSojeong Yi
Sojeong Yi
SRSu-jin Rhee
Su-jin Rhee
HLHyun A Lee
Hyun A Lee
YKYun Kim
Yun Kim
JCJae-Yong Chung
Jae-Yong Chung
Yoon S, et al. Transl Clin Pharmacol. 2019 Sep;27(3):107-114. https://doi.org/10.12793/tcp.2019.27.3.107

30 September 2018 in Genomics & Informatics
Verified
Journal Article
Open access
PDF file
JOJaeseong Oh
Jaeseong Oh
SYSojeong Yi
Sojeong Yi
NGNamyi Gu
Namyi Gu
DSDongseong Shin
Dongseong Shin
KYKyung-Sang Yu
Kyung-Sang Yu
IJIn-Jin Jang
In-Jin Jang
In this report, we present a case study of how pharmacogenomics and pharmacometabolomics can be useful to characterize safety and pharmacokinetic profiles in early phase new drug development clinical trials. During conducting a first-in-human trial for a new molecular entity, we were able to determine the mechanism of dichotomized variability in plasma drug concentrations, which appeared closely related to adverse drug reactions (ADRs) through integrated omics analysis. The pharmacogenomics screening was performed from whole blood samples using the Affymetrix DMET (Drug-Metabolizing Enzymes and Transporters) Plus microarray, and confirmation of genetic variants was performed using real-time polymerase chain reaction. Metabolomics profiling was performed from plasma samples using liquid chromatography coupled with quadrupole time-of-flight mass spectrometry. A GSTM1 null polymorphism was identified in pharmacogenomics test and the drug concentrations was higher in GSTM1 null subjects than GSTM1 functional subjects. The apparent drug clearance was 13-fold lower in GSTM1 null subjects than GSTM1 functional subjects (p < 0.001). By metabolomics analysis, we identified that the study drug was metabolized by cysteinylglycine conjugation in GSTM functional subjects but those not in GSTM1 null subjects. The incidence rate and the severity of ADRs were higher in the GSTM1 null subjects than the GSTM1 functional subjects. Through the integrated omics analysis, we could understand the mechanism of inter-individual variability in drug exposure and in adverse response. In conclusion, integrated multi-omics analysis can be useful for elucidating the various characteristics of new drug candidates in early phase clinical trials.

5 December 2025 in Clinical and Translational Science
Verified
Journal Article
Open access
SYSojeong Yi
Sojeong Yi
CWChia‐Yung Wu
Chia‐Yung Wu
AMAvery McIntosh
Avery McIntosh
MSMaria E. Santaella
Maria E. Santaella
TRTara M. Robinson
Tara M. Robinson
MLMichael Z. Liao
Michael Z. Liao
Cell and gene therapies (CGTs) are transforming medicine by offering potential cures for diseases previously considered untreatable. Despite rapid advancements, challenges remain in optimizing efficacy and safety and ensuring patient accessibility and preference due to high costs and clinical uncertainties, particularly for rare diseases and one‐time administration. The American Society of Clinical Pharmacology & Therapeutics (ASCPT) held a CGT satellite conference in 2025, titled “Cell and Gene Therapy: Transforming Treatment Paradigms for Patient‐Centric Care.” This manuscript summarizes the conference, covering gene therapies and T‐cell immunotherapies from scientific, clinical, and patient‐centered perspectives. Key topics on gene therapy included “platformization” to streamline development, lessons from adeno‐associated virus‐based gene therapies for hemophilia from patient and clinical perspectives, clinical pharmacology, and model‐informed drug development (MIDD) considerations. The conference also highlighted T‐cell immunotherapies including chimeric antigen receptor T therapy (CAR T), focusing on factors affecting cellular kinetics, efficacy, and safety, as well as emerging allogeneic CAR T for autoimmune diseases and MIDD strategies to optimize therapy design and clinical outcomes.